Methylation molecular markers, kits and applications thereof for diagnosis or differentiation of nasopharyngeal carcinoma
By detecting the degree of methylation in the promoter region of the RASSF1A gene in nasopharyngeal carcinoma tissue, and utilizing methylation molecular markers and specific methods, the false negative problem in the early diagnosis of nasopharyngeal carcinoma has been solved, achieving non-invasive and highly sensitive early diagnosis of nasopharyngeal carcinoma.
Patent Information
- Application Number
- CN202411122685.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-08-15
AI Technical Summary
Existing technologies are insufficient for early diagnosis of nasopharyngeal carcinoma, especially due to false negative results when testing for EB virus, and the lack of non-invasive testing methods, resulting in a low early diagnosis rate of nasopharyngeal carcinoma.
Methylation molecular markers are located in the promoter region of the short transcript NM_170713 of the human RASSF1A gene. The degree of methylation in nasopharyngeal swabs is detected by methods such as bisulfite conversion real-time PCR, bisulfite conversion sequencing, or methylation chip sequencing. Primers and probes are designed for the diagnosis or differentiation of nasopharyngeal carcinoma.
It enables non-invasive and sensitive early diagnosis of nasopharyngeal carcinoma, improving the accuracy and sensitivity of early diagnosis, especially since the methylation content in nasopharyngeal carcinoma tissue is significantly higher than that in benign lesion tissue.
Smart Images

Figure CN118621020B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cancer detection, and in particular to a methylation molecular marker, a kit and applications thereof for diagnosing or identifying nasopharyngeal carcinoma. Background Art
[0002] Nasopharyngeal carcinoma (NPC) is an epithelial malignant tumor originating from the nasopharyngeal mucosa, mainly occurring in the top and side walls of the nasopharynx, especially the pharyngeal crypts. The causes of NPC include Epstein-Barr virus infection, genetic factors and environmental factors.
[0003] In terms of symptoms, early stage nasopharyngeal carcinoma often does not cause obvious symptoms. In the advanced stage, symptoms such as tinnitus, hearing loss, nasal congestion, blood in mucus, headache, neck mass and cranial nerve paralysis may occur. If nasopharyngeal carcinoma is diagnosed and treated in the early stage 1 or 2 of its development, the 5-year survival rate can reach more than 90%. Early diagnosis and early treatment are particularly important for nasopharyngeal carcinoma.
[0004] Currently, nasopharyngeal cancer screening is mainly through the detection of Epstein-Barr virus, including the detection of various new Epstein-Barr antibodies and Epstein-Barr virus nucleic acid in the serum. However, among people infected with Epstein-Barr virus, less than 1% will eventually develop nasopharyngeal cancer. There are also a small number of nasopharyngeal cancer patients whose blood cannot detect Epstein-Barr antibodies or Epstein-Barr nucleic acid when cancer is discovered.
[0005] Methylation of tumor suppressor genes is an early event in the malignant transformation of cells. After the tumor suppressor genes are methylated, the expression of tumor suppressor genes is often downregulated, which destroys the balance of carcinogenesis-tumor suppression in cells, causing cells to easily develop in the direction of carcinogenesis. Therefore, directly detecting the methylation degree of tumor suppressor genes in nasopharyngeal mucosal cells can diagnose nasopharyngeal carcinoma early. The present invention has found a group of methylated fragments with high sensitivity, which can diagnose nasopharyngeal carcinoma early in non-invasive sampling of nasopharyngeal swabs. Summary of the invention
[0006] In order to solve the above problems, the present invention provides a methylation molecular marker for diagnosing or identifying nasopharyngeal carcinoma, wherein the methylation molecular marker is located in the promoter region of the shorter transcript NM_170713 of the human RASSF1A gene, and the specific genomic location is hg38 chr3: 50336994-50338198.
[0007] In one embodiment, the methylation molecular markers include at least four of the following groups: the first group: chr3:50338181-50338198, chr3:50338105-50338124, chr3:50338144-50338169, the second group: chr3:50337974-50337990 , chr3:50337901-50337919, chr3:50337920-50337939, the third group: chr3:50337698-50337716, chr3:50337629-50337648, chr3:50337664-50337681; the fourth group chr3:50337456-50337478, chr3:50337345-50337361, chr3:50337366-50337385, the fifth group: chr3:50337201-50337221, chr3:50337119-50337135 、chr3:50337142-50337159.
[0008] In one embodiment, the methylation molecular markers include the following four groups: the first group: chr3:50338181-50338198, chr3:50338105-50338124, chr3:50338144-50338169, the third group: chr3:50337698-50337716, chr3:50337629-50337648, chr3:50337664-50337681; the fourth group: chr3:50337456-50337478 , chr3:50337345-50337361, chr3:50337366-50337385, the fifth group: chr3:50337201-50337221, chr3:50337119-50337135, chr3:50337142-50337159.
[0009] In one embodiment, there is provided a use of the above-mentioned methylation molecular marker in the preparation of a product for diagnosing or identifying nasopharyngeal carcinoma.
[0010] In one embodiment, a reagent for detecting a methylation molecular marker is provided for use in preparing a product for diagnosing or identifying nasopharyngeal carcinoma, wherein the methylation molecular marker includes the above-mentioned methylation molecular marker.
[0011] In one embodiment, in the above application, the reagent for detecting methylation molecular markers includes reagents used in any one or more of the following methods, including at least one of bisulfite conversion fluorescence quantitative PCR method, bisulfite conversion sequencing method, and methylation chip sequencing.
[0012] In one embodiment, a primer, a probe or a combination thereof is provided, with the above-mentioned methylation molecular marker as the target fragment for amplification and detection.
[0013] In one embodiment, a kit for identifying or diagnosing nasopharyngeal carcinoma is provided, wherein the kit is used to detect a methylation molecular marker located in the promoter region of a shorter transcript NM_170713 of the human RASSF1A gene, with a specific genomic location of hg38 chr3: 50336994-50338198.
[0014] In one embodiment, the kit is a kit for identifying whether at least four of the following groups of human chromosomes are methylated: the first group: chr3:50338181-50338198, chr3:50338105-50338124, chr3:50338144-50338169, the second group: chr3:50337974-50337990 , chr3:50337901-50337919, chr3:50337920-50337939, the third group: chr3:50337698-50337716, chr3:50337629-50337648, chr3:50337664-50337681; the fourth group chr3:50337456-50337478, chr3:50337345-50337361, chr3:50337366-50337385, the fifth group: chr3:50337201-50337221, chr3:50337119-50337135 、chr3:50337142-50337159.
[0015] In one embodiment, the kit comprises the following primer and probe combination:
[0016] .
[0017] The present invention analyzes nasopharyngeal carcinoma tissue and nasopharyngeal benign lesion tissue through methylation high-throughput sequencing, and finds that the methylation content of a segment in nasopharyngeal carcinoma tissue is significantly higher than that in nasopharyngeal benign lesion tissue. A group of highly sensitive methylated fragments can be used to diagnose nasopharyngeal carcinoma early in non-invasive nasopharyngeal swabs. The segment is located in the promoter region of the shorter transcript NM_170713 of the RASSF1A gene, which is different from the promoter position of the long transcript of the RASSF1A gene reported in many literatures. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0019] Figure 1 It is a schematic diagram of the genomic DNA sequence segment containing 130 CpGs of the RASSF1A gene;
[0020] Figure 2 This is a schematic diagram of the sequence segment of the genomic DNA sequence of the RASSF1A gene containing 130 CpGs after sulfite treatment. DETAILED DESCRIPTION
[0021] In order to enable those skilled in the art to better understand the technical solutions in this application, the present invention will be further described below in conjunction with the following embodiments. Obviously, the described embodiments are only part of the embodiments of this application, rather than all of the embodiments. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of this application.
[0022] The present invention analyzes nasopharyngeal carcinoma tissue and nasopharyngeal benign lesion tissue by methylation high-throughput sequencing, and finds that the methylation content of a segment in nasopharyngeal carcinoma tissue is significantly higher than that in nasopharyngeal benign lesion tissue. The segment is located in the promoter region of the shorter transcript NM_170713 of the RASSF1A gene, and the promoter region contains 130 CpG islands. The segment is different from the promoter position of the long transcript of the RASSF1A gene reported in many literatures.
[0023] The genomic DNA sequence of the RASSF1A gene contains 130 CpGs. Figure 1 , the sequence of this segment> the sequence after sulfite treatment see Figure 2 , Figure 2In the figure, Y represents C or T base. According to the methylation status, the CpG sites after sulfite treatment are converted to YG and numbered as above, starting from 101. The underlined numbers actually need to be numbered by 100. The last CG is already noted as the 130th CG.
[0024] In the sequence containing 130 CpGs, 5 sequences were selected to design primers and probes for methylation fluorescence quantitative (qMS-PCR) for methylation detection. The boxes represent the locations of upstream and downstream primers; the gray area sequences represent the locations of probes; the primer and probe sequences are shown in Table 1.
[0025] Table 1 Five sequences were selected from the sequence containing 130 CpGs and five qMS-PCR primer probes were designed
[0026] .
[0027] The five probes designed for the five fragments were all labeled with FAM fluorescence; then the primers and probes of different fragments were mixed and combined. Each of them and the following internal reference gene ACTB formed an amplification system in one tube. The internal reference gene primers and probes are shown in Table 2, the PCR reaction system is shown in Table 3, and the specific reaction conditions are shown in Table 4.
[0028] Table 2 Primers and probes for the internal reference gene ACTB
[0029]
[0030] Table 3 PCR reaction system
[0031]
[0032] Table 4 PCR reaction conditions
[0033]
[0034] Fluorescence was collected at 65°C.
[0035] First, each pair of primer probes was combined with the internal reference gene and tested using nasopharyngeal swabs with known clinical information. It was found that qPCR detection of >= 4 fragments was positive and had the best effect in distinguishing benign from malignant tumors.
[0036] Therefore, we mixed primer probes with >= 4 fragments and added internal reference genes to form a two-color qPCR tube to test and screen the best combination. We tested nasopharyngeal swabs from 52 benign lesions or healthy people, and nasopharyngeal swabs from 37 patients with newly diagnosed nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma. When the Ct value of the internal reference gene ACTB was <32, the experiment was successful; the Ct value of the FAM channel of qMS-PCR was <40, the methylation test was considered positive. The results are shown in Table 5 below. The clinical information of the cases and the specific methylation results are shown in Tables 6, 7 and 8.
[0037] Table 5. Methylation detection results of primer-probe combinations greater than or equal to 4 pairs
[0038]
[0039] Table 6. Nasopharyngeal swab test results of 52 patients with benign lesions or healthy subjects and 37 patients with newly diagnosed nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma1
[0040]
[0041] Table 7. Nasopharyngeal swab test results of 52 patients with benign lesions or healthy subjects and 37 patients with newly diagnosed nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma2
[0042]
[0043] Table 8. Results of nasopharyngeal swab tests using 52 patients with benign lesions or healthy subjects and 37 patients with newly diagnosed nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma
[0044]
[0045] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.
[0046] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.
Claims
1. A methylation molecular marker for diagnosis or identification of nasopharyngeal carcinoma, characterized in that: The methylation molecular marker is located in the promoter region of the shorter transcript NM_170713 of the human RASSF1A gene, and the specific genomic location is hg38 chr3:50336994-50338198; the methylation molecular marker includes at least four of the following groups: the first group: chr3:50338181-50338198, chr3:50338105-50338124, chr3:50338144-50338169, the second group: chr3:50337974-50337990 , chr3:50337901-50337919, chr3:50337920-50337939, the third group: chr3:50337698-50337716, chr3:50337629-50337648, chr3:50337664-50337681; the fourth group chr3:50337456-50337478, chr3:50337345-50337361, chr3:50337366-50337385, the fifth group: chr3:50337201-50337221, chr3:50337119-50337135 、chr3:50337142-50337159.
2. The methylation molecular marker according to claim 1, characterized in that The methylation molecular markers include the following four groups: the first group: chr3:50338181-50338198, chr3:50338105-50338124, chr3:50338144-50338169, the third group: chr3:50337698-50337716, chr3:50337629-50337648, chr3:50337664-50337681; the fourth group chr3:50337456-50337478, chr3:50337345-50337361, chr3:50337366-50337385, the fifth group: chr3:50337201-50337221 , chr3:50337119-50337135, chr3:50337142-50337159.
3. Use of the methylation molecular marker according to any one of claims 1-2 in the preparation of a product for diagnosing or identifying nasopharyngeal carcinoma.
4. Use of a reagent for detecting methylation molecular markers in the preparation of a product for diagnosing or identifying nasopharyngeal carcinoma, characterized in that: The methylation molecular marker comprises the methylation molecular marker according to any one of claims 1-2.
5. The use according to claim 4, characterized in that: The reagents for detecting methylation molecular markers include reagents used in any one or more of the following methods, wherein the methods include at least one of bisulfite conversion fluorescence quantitative PCR method, bisulfite conversion sequencing method, and methylation chip sequencing.
6. A kit for identifying or diagnosing nasopharyngeal carcinoma, characterized in that: The kit is used to detect that the methylation molecular marker is located in the promoter region of the shorter transcript NM_170713 of the human RASSF1A gene, and the specific genomic location is hg38 chr3:50336994-50338198. The kit is a kit for identifying whether at least four of the following groups of human chromosomes are methylated: the first group: chr3:50338181-50338198, chr3:50338105-50338124, chr3:50338144-50338169, the second group: chr3:50337974-50337990 , chr3:50337901-50337919, chr3:50337920-50337939, the third group: chr3:50337698-50337716, chr3:50337629-50337648, chr3:50337664-50337681; the fourth group chr3:50337456-50337478, chr3:50337345-50337361, chr3:50337366-50337385, the fifth group: chr3:50337201-50337221, chr3:50337119-50337135 , chr3:50337142-50337159; the kit comprises the following primer and probe combinations: 。
